Stagezero Life Sciences Stock Net Income
| SZLSF Stock | USD 0.0005 0.00 0.00% |
As of the 9th of February, StageZero Life has the Risk Adjusted Performance of (0.09), coefficient of variation of (812.40), and Variance of 123.26. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of StageZero Life Sciences, as well as the relationship between them. Please validate StageZero Life Sciences mean deviation and treynor ratio to decide if StageZero Life is priced more or less accurately, providing market reflects its prevalent price of 5.0E-4 per share. As StageZero Life Sciences appears to be a penny stock we also recommend to double-check its information ratio numbers.
StageZero Life's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing StageZero Life's valuation are provided below:StageZero Life Sciences does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. StageZero |
StageZero Life 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to StageZero Life's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of StageZero Life.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in StageZero Life on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding StageZero Life Sciences or generate 0.0% return on investment in StageZero Life over 90 days. StageZero Life is related to or competes with Medigene, Identa Corp, Epigenomics, Vaccinex, and Invitro International. StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecu... More
StageZero Life Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure StageZero Life's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess StageZero Life Sciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 90.2 |
StageZero Life Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for StageZero Life's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as StageZero Life's standard deviation. In reality, there are many statistical measures that can use StageZero Life historical prices to predict the future StageZero Life's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (1.50) | |||
| Total Risk Alpha | (2.47) | |||
| Treynor Ratio | (0.90) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of StageZero Life's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
StageZero Life February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.89) | |||
| Mean Deviation | 2.69 | |||
| Coefficient Of Variation | (812.40) | |||
| Standard Deviation | 11.1 | |||
| Variance | 123.26 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (1.50) | |||
| Total Risk Alpha | (2.47) | |||
| Treynor Ratio | (0.90) | |||
| Maximum Drawdown | 90.2 | |||
| Skewness | (8.12) | |||
| Kurtosis | 66.0 |
StageZero Life Sciences Backtested Returns
StageZero Life Sciences owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.12, which indicates the firm had a -0.12 % return per unit of risk over the last 3 months. StageZero Life Sciences exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate StageZero Life's Risk Adjusted Performance of (0.09), variance of 123.26, and Coefficient Of Variation of (812.40) to confirm the risk estimate we provide. The entity has a beta of 1.53, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, StageZero Life will likely underperform. At this point, StageZero Life Sciences has a negative expected return of -1.41%. Please make sure to validate StageZero Life's mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and day median price , to decide if StageZero Life Sciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
StageZero Life Sciences has no correlation between past and present. Overlapping area represents the amount of predictability between StageZero Life time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of StageZero Life Sciences price movement. The serial correlation of 0.0 indicates that just 0.0% of current StageZero Life price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, StageZero Life Sciences reported net income of (7.48 Million). This is 102.19% lower than that of the Healthcare sector and 104.32% lower than that of the Diagnostics & Research industry. The net income for all United States stocks is 101.31% higher than that of the company.
StageZero Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses StageZero Life's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of StageZero Life could also be used in its relative valuation, which is a method of valuing StageZero Life by comparing valuation metrics of similar companies.StageZero Life is currently under evaluation in net income category among its peers.
StageZero Fundamentals
| Return On Equity | -1.69 | |||
| Return On Asset | -0.61 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (1.99) % | |||
| Current Valuation | 6.93 M | |||
| Shares Outstanding | 101.53 M | |||
| Shares Owned By Insiders | 2.60 % | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.17 X | |||
| Revenue | 5.07 M | |||
| Gross Profit | 1.18 M | |||
| EBITDA | (6.77 M) | |||
| Net Income | (7.48 M) | |||
| Cash And Equivalents | 90.63 K | |||
| Total Debt | 582.46 K | |||
| Debt To Equity | 0.95 % | |||
| Current Ratio | 0.13 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (8.95 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 80 | |||
| Beta | 1.02 | |||
| Market Capitalization | 5.39 M | |||
| Total Asset | 10.65 M | |||
| Z Score | 5.4 | |||
| Net Asset | 10.65 M |
About StageZero Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze StageZero Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of StageZero Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of StageZero Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in StageZero Pink Sheet
StageZero Life financial ratios help investors to determine whether StageZero Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in StageZero with respect to the benefits of owning StageZero Life security.